Key points are not available for this paper at this time.
Cooccurrence of multiple actionable protein/pathways alterations in each subtype indicates unique therapeutic vulnerabilities and opportunities for optimal combination therapy for this understudied and heterogeneous disease.
Ferrarotto et al. (Tue,) studied this question.